Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2—azithromycin trial

BACKGROUND: The rapid emergence and the high disease burden of the novel coronavirus SARS-CoV-2 have created a medical need for readily available drugs that can decrease viral replication or blunt the hyperinflammatory state leading to severe COVID-19 disease. Azithromycin is a macrolide antibiotic,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyselinck, Iwein, Liesenborgs, Laurens, Landeloos, Ewout, Belmans, Ann, Verbeke, Geert, Verhamme, Peter, Vos, Robin, Janssens, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871018/
https://www.ncbi.nlm.nih.gov/pubmed/33563325
http://dx.doi.org/10.1186/s13063-021-05033-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871018/
https://www.ncbi.nlm.nih.gov/pubmed/33563325
http://dx.doi.org/10.1186/s13063-021-05033-x

Ejemplares similares